» Articles » PMID: 26212075

Chemokine (C-X-C Motif) Ligand 11 Levels Predict Survival in Cirrhotic Patients with Transjugular Intrahepatic Portosystemic Shunt

Abstract

Background & Aims: Chemokines, such as CXCR3-ligands, have been identified to play an important role during hepatic injury, inflammation and fibrosis. While CXCL9 is associated with survival in patients receiving transjugular intrahepatic portosystemic shunt (TIPS), the role of CXCL11 in severe portal hypertension remains unknown.

Methods: CXCL11-levels were measured in 136 patients with liver diseases, and 63 healthy controls. In further 47 cirrhotic patients receiving TIPS, CXCL11 levels were measured in portal and hepatic veins at TIPS insertion by cytometric bead array. CXCL11-levels were measured in 23 patients in cubital vein and right atrium, whereas in 24 patients in portal and hepatic blood at an invasive reevaluation.

Results: CXCL11-levels were increased with the severity of liver fibrosis. CXCL11-levels from portal, hepatic and cubital veins and right atrium showed a highly significant correlation among each other in these patients. Furthermore, levels of CXCL11 from the right atrium were significantly higher than those from cubital vein. Interestingly, patients with alcoholic cirrhosis had significantly lower CXCL11-levels, than other aetiologies of cirrhosis. After TIPS, CXCL11 levels correlated with the degree of portal pressure and patients with higher CXCL11-levels in portal and hepatic veins showed higher mortality. Multivariate analysis revealed hepatic CXCL11-levels before TIPS, creatinine and age as independent predictors for survival in TIPS patients, whereas MELD score and low portal CXCL11-levels after TIPS predicted long-term survival.

Conclusion: CXCL11 levels are mainly increased in patients with non-alcoholic cirrhosis and high portal pressure. Moreover, levels of CXCL11 might predict long-time survival of cirrhotic patients bearing TIPS.

Citing Articles

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis.

Tiede A, Stockhoff L, Liu Z, Rieland H, Mauz J, Ohlendorf V Clin Mol Hepatol. 2024; 31(1):240-255.

PMID: 39568127 PMC: 11791575. DOI: 10.3350/cmh.2024.0587.


Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.

Loosen S, Benz F, Mohr R, Reuken P, Wirtz T, Junker L JHEP Rep. 2024; 6(5):101054.

PMID: 38681861 PMC: 11053213. DOI: 10.1016/j.jhepr.2024.101054.


The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.

Wang J, Ouyang X, Zhu W, Yi Q, Zhong J Cancer Control. 2024; 31:10732748241241162.

PMID: 38533911 PMC: 10976495. DOI: 10.1177/10732748241241162.


High Interleukin-8 Levels Associated With Decreased Survival in Patients With Cirrhosis Following Transjugular Intrahepatic Portosystemic Shunt.

Liu G, Wang X, Yang T, Yan Y, Xiang T, Yang L Front Med (Lausanne). 2022; 9:829245.

PMID: 35295601 PMC: 8918632. DOI: 10.3389/fmed.2022.829245.


Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis.

Wirtz T, Reuken P, Jansen C, Fischer P, Bergmann I, Backhaus C JHEP Rep. 2021; 3(2):100221.

PMID: 33659891 PMC: 7890204. DOI: 10.1016/j.jhepr.2020.100221.